Journals / Acta Medica Alanya / 2026 / Cilt: 9 Sayı: 2

Is It Parathyroid Hyperplasia or Parathyroid Adenoma?

Paratiroid hiperplazisi mi? Paratiroid adenomu mu?

Eren Gürkan(HATAY MUSTAFA KEMAL ÜNİVERSİTESİ, TAYFUR ATA SÖKMEN TIP FAKÜLTESİ)0000-0002-3118-4549
Pages
130–135
Publication Date
2025-08-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The possibility of parathyroid adenoma should be kept in mind in patients who are not in the risk group for parathyroid hyperplasia but who have complete biochemical recovery findings in the short and long term.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Some of the patients who were evaluated and operated due to asymptomatic primary hyperparathyroidism were reported as parathyroid hyperplasia in their pathology.
📊
Key Findings & Data:Methods: Data of patients who underwent parathyroid adenomectomy with the diagnosis of asymptomatic primary hyperparathyroidism in our unit between 2017 and 2024 were evaluated.
💡
Conclusion & Impact:The possibility of parathyroid adenoma should be kept in mind in patients who are not in the risk group for parathyroid hyperplasia but who have complete biochemical recovery findings in the short and long term.
🔬Design:Araştırma Makalesi
📍Scope:2017 Verileri
⚙️Variables:paratiroid tümörleri · primer hiperparatiroidi · hiperkalsemi

Abstract

Aim: Some of the patients who were evaluated and operated due to asymptomatic primary hyperparathyroidism were reported as parathyroid hyperplasia in their pathology. We aimed to evaluate the postoperative short-term follow-up results of these patients who were not in the hyperplasia risk group. Methods: Data of patients who underwent parathyroid adenomectomy with the diagnosis of asymptomatic primary hyperparathyroidism in our unit between 2017 and 2024 were evaluated. In the risk group of parathyroid hyperplasia, those who have had a second parathyroid surgery, those with familial inheritance, genetic syndromes (MEN 1, etc.), drug and ionizing radiation effects, and chronic kidney disease were excluded from the study. The data of 17 patients with parathyroid hyperplasia whose preoperative diagnosis was parathyroid adenoma were evaluated in detail. Results: The mean age was 57,2 years and the female/male ratio was (15/2). Lesion size was 1.6±0,6 cm. The mean postoperative follow-up period was 30,4±31,3 months. Preoperative serum Ca: 11,3±0.7 mg/dl, P: 2,6±0,6 mg/dl and PTH: 322±359 pg/ml, Postoperative serum Ca: 9,4±0,4 mg/dl, P: 3,4±0,6 mg/dl and PTH: 40±23 pg/ml, and significant changes were observed compared to preoperative levels (p<0,001, p=0,024, p<0,001, respectively). Conclusion: Patients who underwent surgery with a preliminary diagnosis of parathyroid adenoma should be questioned in detail in terms of clinical and pathological diagnosis in the postoperative period. The possibility of parathyroid adenoma should be kept in mind in patients who are not in the risk group for parathyroid hyperplasia but who have complete biochemical recovery findings in the short and long term.

Özet

Amaç: Asemptomatik primer hiperparatiroidizm kliniği nedeniyle değerlendirilip opere edilen hastaların bir kısmının patolojisi paratiroid hiperplazisi olarak raporlanmaktadır. Hiperplazi risk grubunda yer almayan bu hastalarımızın postoperatif kısa dönem takip sonuçlarını değerlendirmeyi amaçladık. Yöntem:2017-2024 tarihleri arasında ünitemizde asemptomatik primer hiperparatiroidizm tanısıyla paratiroid adenomektomi operasyonu olan hasta verileri değerlendirildi. Paratiroid hiperplazisi risk grubu; ikinci kez paratiroid operasyonu olanlar, ailesel geçişliler, genetik sendromlar (MEN 1 vb.), ilaç ve iyonize radyasyon etkisi ve kronik böbrek hastalığı çalışma dışı bırakıldı. Preoperatif ön tanısı paratiroid adenom olan 17 paratiroid hiperplazili hastanın verileri detaylı olarak değerlendirildi. Bulgular: Ortalama yaş 57,2 yıl ve kadın/erkek oranı (15/2) idi. Lezyon büyüklüğü 1,6±0,6 cm. Postoperatif takip süresi ortalama 30,4 ±31,3 ay. Preoperatif serum Ca: 11,3±0,7 mg/dl, P: 2,6±0,6 mg/dl ve PTH: 322±359 pg/ml, Postoperatif serum Ca: 9,4±0,4 mg/dl, P: 3,4±0,6 mg/dl ve PTH: 40±23 pg/ml ile preoperatif düzeylerine göre anlamlı değişim gözlendi (sırasıyla p<0,001, p=0,024, p<0,001). Sonuç: Paratiroid adenom ön tanısıyla opere olan hastaların paratiroid hiperplazisi patolojik tanıları postoperatif dönemde klinik ve patolojik olarak detaylı sorgulanmalıdır. Paratiroid hiperplazisi için risk grubunda olmayan fakat kısa ve uzun dönemde biyokimyasal olarak tam iyileşme bulguları gözlenen hastalarda paratiroid adenomu ihtimali akılda tutulmalıdır.

🔖

Cite This Article

Gürkan, E. (2025). Is It Parathyroid Hyperplasia or Parathyroid Adenoma?. Acta Medica Alanya, Cilt: 9 Sayı: 2, 130–135. https://ajindex.com/articles/1349472

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (25)

  1. Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98(3):1122-9. doi: 10.1210/jc.2012-4022.
  2. Rizzoli R, BonjourJ-P. Physiology of calcium and phosphate homeostasis. In Seibel MJ, Robins SP, Bilezikian JP, eds. Dynamics of Bone and Cartilage Metabolism. San Diego, CA: Academic Press; 1999 pp 247-260.
  3. Brown EM. Role of the calcium-sensing receptor in extracellular calcium homeostasis. Best Pract Res Clin Endocrinol Metab. 2013;27(3):333-43. doi: 10.1016/j.beem.2013.02.006.
  4. Hannan FM, Kallay E, Chang W, Brandi ML, Thakker RV. The calcium- sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol. 2018;15(1):33-51. doi: 10.1038/s41574-018-0115-0.
  5. Singh P, Bhadada SK, Dahiya D, Arya AK, Saikia UN, Sachdeva N, et al. Reduced calcium sensing receptor (CaSR) expression is epigenetically deregulated in parathy- roid adenomas. J Clin Endocrinol Metab. 2020;105(9):3015-3024. doi: 10.1210/clinem/dgaa419.
  6. Bilezikian JP. Primary hyperparathyroidism. J Clin Endocrinol Metab. 2018;103(11):3993-4004. doi: 10.1210/jc.2018-01225.
  7. Corbetta S, Mantovani G, Lania A, Borgato S, Vicentini L, Beretta E, et al. Calcium-sensing recep- tor expression and signalling in human parathyroid adenomas and primary hyperplasia. Clin Endocrinol (Oxf). 2000;52(3): 339-48. doi: 10.1046/j.1365-2265.2000.00933.x.
  8. DeLellis RA. Parathyroid tumors and related disorders. Mod Pathol. 2011;24 Suppl 2:S78-93. doi: 10.1038/modpathol.2010.132.
  9. Mihai R, Sitges-Serra A. Multigland primary hyperparathyroidism-frequently considered, seldom encountered. Langenbecks Arch Surg. 2015;400(8):863-6. doi: 10.1007/s00423-016-1373-8.
  10. Rahbari R, Holloway AK, He M, Khanafshar E, Clark OH, Kebebew E. Identification of differentially expressed microRNA in parathyroid tumors. Ann Surg Oncol. 2011;18(4):1158-65. doi: 10.1245/s10434-010-1359-7.
  11. Erickson LA, Mete O, Juhlin CC, Perren A, Gill AJ. Overview of the 2022 WHO Classification of Parathyroid Tumors. Endocr Pathol. 2022;33(1):64-89. doi: 10.1007/s12022-022-09709-1.
  12. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3561-9. doi: 10.1210/jc.2014-1413.
  13. Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, Minisola S, et al. International Workshop on Primary Hyperparathyroidism. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J Bone Miner Res. 2022;37(11):2293-314. doi: 10.1002/jbmr.4677.
  14. Ozderya A, Temizkan S, Cetin K, Ozugur S, Gul AE, Aydin K. The results of parathyroid hormone assay in parathyroid aspirates in pre-operative localization of parathyroid adenomas for focused parathyroidectomy in patients with negative or suspicious technetium-99M-sestamibi scans. Endocr Pract. 2017;23(9):1101–06. doi: 10.4158/EP171921.OR
  15. Fraser W. D. Hyperparathyroidism. Lancet. 2009;374(9684):145–58. doi: 10.1016/S0140-6736(09)60507-9.
  16. Foster T, Dy B, Rocco R, Mckenzie T, Thompson G, Wermers R, et al. Routine Use of Preoperative Neck Ultrasound in Primary Hyperparathyroidism Identifies Coexisting Thyroid Disease and Improves Parathyroid Localization. Am Surg. 2022;88(2):254-259. doi: 10.1177/0003134821991991.
  17. Castellana M, Virili C, Palermo A, Giorgino F, Giovanella L, Trimboli P. Primary hyperparathyroidism with surgical indication and negative or equivocal scintigraphy: safety and reliability of PTH washout. A systematic review and meta-analysis. Eur J Endocrinol. 2019;181(3):245-253. doi: 10.1530/EJE-19-0160.
  18. Allendorf J, DiGorgi M, Spanknebel K, Inabnet W, Chabot J, Logerfo P. 1112 consecutive bilateral neck explorations for primary hyperparathyroidism. World J Surg. 2007;31(11):2075-80. doi: 10.1007/s00268-007-9068-5.
  19. van der Walt J. Pathology of the parathyroid glands. Diagnostic Histopathology 2012;18:221–33. doi: 10.1016/j. mpdhp.2012.03.006.
  20. Pang T, Stalberg P, Sidhu S, Sywak M, Wilkinson M, Reeve TS, et al. Minimally invasive parathyroidectomy using the lateral focused mini-incision technique without intraoperative parathyroid hormone monitoring. Br J Surg. 2007;94(3):315-9. doi: 10.1002/bjs.5608.
  21. Duan K, Gomez Hernandez K, Mete O. Clinicopathological correlates of hyperparathyroidism. J Clin Pathol. 2015;68(10):771-87. doi: 10.1136/jclinpath-2015-203186.
  22. Singh P, Bhadada SK, Dahiya D, Arya AK, Saikia UN, Sachdeva N, et al. Reduced Calcium Sensing Receptor (CaSR) Expression Is Epigenetically Deregulated in Parathyroid Adenomas. J Clin Endocrinol Metab. 2020;105(9):3015–24. doi: 10.1210/clinem/dgaa419.
  23. Johnson SJ. Changing clinicopathological practice in parathyroid disease. Histopathology. 2010;56(7):835-51. doi: 10.1111/j.1365-2559.2010.03515.x.
  24. Friedman E, Sakaguchi K, Bale AE, Falchetti A, Streeten E, Zimering MB, et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N Engl J Med. 1989;321(4):213-8. doi: 10.1056/NEJM198907273210402.
  25. Mariathasan S, Andrews K, Thompson E, Armstrong R, Park SM, Casey R. Genetic testing for hereditary hyperparathyroidism in a large UK cohort. Endocr Abstr. 2019;63(OC1):1. doi: 10.1530/endoabs.63.OC1.1.